The ROE as of December 2024 (TTM) for Nautilus Biotechnology, Inc. (NAUT) is -28.85%

According to Nautilus Biotechnology, Inc.’s latest financial reports and current stock price. The company's current ROE is -28.85%. This represents a change of 298.74% compared to the average of -7.23% of the last 4 quarters.

Nautilus Biotechnology, Inc. (NAUT) Historical ROE (quarterly & annually)

How has NAUT ROE performed in the past?

The mean historical ROE of Nautilus Biotechnology, Inc. over the last ten years is 2.09%. The current -28.85% ROE has changed -101.38% with respect to the historical average. Over the past ten years (40 quarters), NAUT's ROE was at its highest in in the December 2018 quarter at 12.53%. The ROE was at its lowest in in the June 2020 quarter at -25257.85%.

Nautilus Biotechnology, Inc. (NAUT) ROE by Quarter and Year

Discovering the peaks and valleys of Nautilus Biotechnology, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Nautilus Biotechnology, Inc. (NAUT) Average ROE

How has NAUT ROE performed in the past?

The current ROE of Nautilus Biotechnology, Inc. (NAUT) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Nautilus Biotechnology, Inc. (NAUT) ROE vs. Peers

How is NAUT’s ROE compared to its peers?

Nautilus Biotechnology, Inc.’s ROE is greater than C4 Therapeutics, Inc. (-42.45%), greater than Kymera Therapeutics, Inc. (-24.96%), less than Foghorn Therapeutics Inc. (167.93%), greater than Revolution Medicines, Inc. (-33.67%), greater than Century Therapeutics, Inc. (-66.58%), greater than BioAtla, Inc. (-187.30%), greater than PMV Pharmaceuticals, Inc. (-24.20%), greater than Caribou Biosciences, Inc. (-45.46%), greater than Homology Medicines, Inc. (-100.91%), less than Precision BioSciences, Inc. (17.63%), greater than Beam Therapeutics Inc. (-16.22%), greater than MediciNova, Inc. (-20.70%), less than Eliem Therapeutics, Inc. (0%), greater than Molecular Partners AG (-39.16%), less than Champions Oncology, Inc. (66.22%), greater than Cyteir Therapeutics, Inc. (-9.44%), greater than Anebulo Pharmaceuticals, Inc. (-184.40%), greater than Rezolute, Inc. (-69.83%), greater than HCW Biologics Inc. (-2516.87%),

Build a custom stock screener for Nautilus Biotechnology, Inc. (NAUT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Nautilus Biotechnology, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Nautilus Biotechnology, Inc. (NAUT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Nautilus Biotechnology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.